# Many People Never Reach the Dose

By Ruth Calder, Enforcement Editor (https://glpwatchdog.org/authors/ruth-calder) | Published: 2026-08-19 | Updated: 2026-11-10

Canonical page: https://glpwatchdog.org/research/most-people-never-reach-the-dose

> Only 58% of people starting semaglutide reached the recommended maintenance dose after four weeks, and 21% stayed on the starting dose. More than half of oral semaglutide starters stopped altogether.

## Key points

- Only 58% reached maintenance dosing after four weeks; 21% stayed on the starting dose.
- Discontinuation: 36.9% dulaglutide, 46.4% injected semaglutide, 55.8% ORAL semaglutide.
- By the tenth prescription, 44.0% of injected semaglutide users were still on 0.5 mg, a step below the 1 mg top dose prescribed.
- A stall at a low dose may mean under-dosing, not non-response.

There is a simple explanation for why real-world results look worse than trial results, and it is not that patients are different. A UK population study found that only **58%** of people starting semaglutide reached the recommended maintenance dose after four weeks, and **21% were still on the starting dose**, the one that exists to be tolerated rather than to work.[1]

## Where people end up

By the tenth prescription, the commonest subcutaneous semaglutide doses were 0.5 mg (44.0%) and 1 mg (48.6%). The 2 mg dose was not prescribed in this database during the study period, so 1 mg was the top of the ladder these patients were on.[1] Nearly half were still a step below it after ten prescriptions, which is most of a year.

Escalation was faster in people with higher BMI, and the authors found no further variation by other patient characteristics, including established cardiovascular disease. Delayed escalation was, in their words, frequent across all patient stratifications.[1] The ladders themselves differ in length: [Saxenda’s dose ladder](https://glpwatchdog.org/research/cheat-sheets/saxenda-dose-ladder-cheat-sheet) is the shortest climb to a full dose among the GLP-1 weight drugs, 0.6 mg a day raised by 0.6 mg each week to 3.0 mg in week five, where the others take months to reach their top dose.

> A trial escalates on protocol. Ordinary care escalates when someone remembers to.

## And half of them stop

*Discontinuation rates in UK primary care, by drug and formulation.*

| Drug | Discontinued |
| --- | --- |
| Dulaglutide | 36.9% |
| Semaglutide, subcutaneous | 46.4% |
| **Semaglutide, oral** | **55.8%** |

More than half of the people who started the oral version stopped.[1] That is the formulation sold on convenience, yet it has the strictest daily conditions: an empty stomach on waking, then a wait before anything else (see [travel and time zones](https://glpwatchdog.org/research/glp1-travel-and-time-zones)). A convenient format does not make for a convenient routine.

The worst nausea in our [side-effect ranking](https://glpwatchdog.org/research/which-glp1-has-the-worst-side-effects) belonged to another oral drug, orforglipron. That says nothing directly about oral semaglutide.

## Why this reframes so much else

We wrote recently that real-world data shows outcome differences by race and ethnicity where randomized trials showed none, and argued the gap lies in access, continuity and titration rather than in patients (see [who responds in the real world](https://glpwatchdog.org/research/who-responds-in-the-real-world)). This study puts numbers on the titration half of that argument.

If a fifth of people are still on the starting dose when the first step up is due and nearly half stop altogether, then a large part of “the drug worked less well than in trials” is really “the drug was never taken at the dose it was tested at, for the duration it was tested for”. Those are different problems with different solutions. Stopping itself splits the same way: [not tolerating a drug and not taking it reliably have different predictors](https://glpwatchdog.org/research/not-taking-it-and-not-tolerating-it).

> **This is also why plateau advice so often misses.** Someone whose weight loss has stalled at a low dose is not a non-responder; they may simply be under-dosed. That is a conversation about titration with a prescriber, and it is a much more likely explanation than needing a different drug. Our article on [switching](https://glpwatchdog.org/research/switching-between-glp1-drugs) covers why changing drugs restarts the ladder rather than skipping it.

## What this does not establish

- **It is a type 2 diabetes population in UK primary care.** Dosing targets, prescribing incentives and follow-up patterns differ from US weight-management practice.
- **It does not say why people stopped.** Side effects, cost, supply and simply not returning are all in there, undifferentiated.
- **Slow escalation is sometimes correct.** Holding a dose because someone is nauseated is good medicine, not a failure, and the labels build that judgment in.
- **Higher is not automatically better.** For tirzepatide the step from 10 to 15 mg added little on average, as [which Zepbound dose works best](https://glpwatchdog.org/research/which-zepbound-dose-works-best) shows. The point is that most people never get the chance to find out.

## Frequently asked questions

### Why do real-world results look worse than trial results?

In part because many people never reach the dose. In a UK population study, only 58% of semaglutide initiators reached recommended maintenance doses after four weeks and 21% remained on the starting dose. Trials escalate on protocol; ordinary care frequently does not.

### How many people stop taking these drugs?

In this cohort, 36.9% discontinued dulaglutide, 46.4% subcutaneous semaglutide and 55.8% oral semaglutide. More than half of the people who started the oral version stopped.

### Why is the oral version worst?

The study does not say, but the oral formulation has the strictest daily conditions. It is taken on waking on an empty stomach, with a wait before food or other tablets. The format is more convenient than an injection; the routine around it is not.

### Does this mean my weight loss stalled because my dose is too low?

It is a much more likely explanation than most people assume. Raise it with a prescriber before concluding the drug does not work for you. Someone stalled at a starting dose is not a non-responder.

### Is slow escalation always a mistake?

No. Holding a dose because someone cannot tolerate the next step is good medicine, and every label builds that judgment in. The finding is that delayed escalation was frequent across all groups, not that any individual decision was wrong.

## References

1. Ulrich FS, Napoli N, Nielsen MF, et al. Real-world persistence and dose titration of GLP-1 receptor agonists in type 2 diabetes: A UK population-based cohort study. Diabetes, Obesity and Metabolism. 2026. PMID: 41703773. https://pubmed.ncbi.nlm.nih.gov/41703773/

---

Cite as: GLP Watchdog, Ruth Calder, "Many People Never Reach the Dose", published 2026-08-19, updated 2026-11-10. https://glpwatchdog.org/research/most-people-never-reach-the-dose

Canonical HTML page: https://glpwatchdog.org/research/most-people-never-reach-the-dose

Medical disclaimer: Nothing here is medical advice. We report on this subject; we do not treat anyone. Whether to begin a medication, supplement, or treatment, whether to adjust it, and whether to stop are questions for a clinician licensed to answer them, who knows your history.
